Evidence map›Paper›PMID 30949931›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.

V T Ferrero, M M Oset, J P Masferrer, E H Pardo, E J Sorolla, S C Largo, PrevaDIOR Study Group

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Treatment-related pain in refractory cancer pain: prevalence, mechanisms, and clinical implications in a tertiary referral cohort.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

V T FerreroDepartment of Radiation Oncology, Hospital Universitary de Sant Joan D'Alacant, Carretera Nacional 332 Alicante-Valencia s/n, Sant Joan D'Alacant, 03550, Alicante, Spain. doctor.vicente.tormo@gmail.com.ORCID http://orcid.org/0000-0001-6665-9789
M M OsetDepartment of Radiation Oncology, Hospital Universitary de Sant Joan D'Alacant, Carretera Nacional 332 Alicante-Valencia s/n, Sant Joan D'Alacant, 03550, Alicante, Spain.
J P MasferrerDepartment of Radiation Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
E H PardoDepartment of Radiation Oncology, Hospital Universitario de Araba, Vitoria, Spain.
E J SorollaDepartment of Radiotherapy, Hospital Clínico Universitario de Valencia, Valencia, Spain.
S C LargoDepartment of Radiation Oncology, Hospital Clínico San Carlos, Madrid, Spain.
PrevaDIOR Study Group
Hospital Universitari Sant Joan D'Alacant · ESHospital Clínico San Carlos · ESHospital Clínico Universitario de Valencia · ESHospital Universitario Araba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia.

methodsThis observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients.

resultsThe prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients.

conclusionsThis study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.

Indexed as

AdultAgedAged, 80 and overAnus NeoplasmsBreakthrough PainCancer PainChi-Square DistributionCross-Sectional StudiesEndometrial NeoplasmsFemaleHumansMaleMiddle AgedNeoplasmsPainPrevalenceBreakthrough painPelvic 3D radiotherapyProctalgia

Identifiers

PMID30949931
OpenAlexW2929425977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.